<DOC>
	<DOCNO>NCT01691755</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study ass efficacy , safety tolerability aleglitazar monotherapy compare placebo patient type 2 diabetes mellitus previously receive anti-hyperglycemic therapy . Patients randomize receive oral dos 150 mcg aleglitazar daily placebo . The anticipated time study treatment 26 week .</brief_summary>
	<brief_title>A Study Aleglitazar Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis diabetes mellitus , type 2 within 12 month prior screen Patients receive antihyperglycemic medication least 12 week prior screen longer 3 consecutive month past HbA1c &gt; /=7 % &lt; /=9.5 % screen within 4 week prior screen prerandomization visit Fasting plasma glucose &lt; /=240 mg/dL prerandomization visit Agreement maintain diet exercise habit study Patients Type 1 diabetes mellitus , secondary diabetes , diabetes result pancreatic injury , acute metabolic diabetic complication within past 6 month Any previous treatment thiazolidinedione dual peroxisome proliferator activate receptor ( PPAR ) agonist Any body weight lower lipoproteinmodifying therapy within 12 week prior screen ( except stable dose statin ) Symptomatic congestive heart failure classify New York Heart Association class IIIV screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>